UK markets close in 1 hour 58 minutes

Galapagos NV (GLPG)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
50.24-1.01 (-1.97%)
As of 09:32AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close51.25
Open51.10
Bid50.38 x 900
Ask50.45 x 800
Day's range50.20 - 50.52
52-week range46.41 - 119.81
Volume7,986
Avg. volume234,646
Market cap3.293B
Beta (5Y monthly)0.40
PE ratio (TTM)N/A
EPS (TTM)-3.06
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est83.13
  • Globe Newswire

    Galapagos increases share capital through subscription right exercises

    Mechelen, Belgium; 3 December 2021, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 22,600 new ordinary shares on 3 December 2021, for a total capital increase (including issuance premium) of €578,700.00. Pursuant to the subscription right exercise program of Galapagos’ management board, members of the management board automatically are committed to exercise a minimum number o

  • Globe Newswire

    Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease

    Mechelen, Belgium; 22 November 2021, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces completion of recruitment in the MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737 in patients with autosomal dominant polycystic kidney disease (ADPKD). MANGROVE is a randomized, double-blind, placebo-controlled trial evaluating a once-daily oral dose of GLPG2737 (NCT04578548). The drug candidate or placebo is administered for 52 weeks, followed by an open-label extension period of

  • Globe Newswire

    Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis

    Mechelen, Belgium; 15 November 2021; 16.45 CET; Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the European Commission has granted marketing authorization for Jyseleca® (filgotinib 200mg tablets) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC). The European Commission approved an additional indication for Jyseleca, an oral, once-daily, JAK1 preferential inhibitor, for adult patients with moderately to severely active UC who have had an